Lung Diseases, Interstitial Clinical Trials
5 recruiting trials for Lung Diseases, Interstitial. Eligibility criteria explained in plain English.
TrialFinderData lists 5 Lung Diseases, Interstitial clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by University of Sydney (1), Matthias Griese (1), Boehringer Ingelheim (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Pulmonary Fibrosis self-management package and smartphone application (behavioral, 1 trial), followed by Hospital-based pulmonary rehabilitation, Home-based pulmonary rehabilitation.
Track Lung Diseases, Interstitial trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease
The goal of this clinical trial is to compare REBUILD-SM (a purpose-built smartphone app and self-management package) with standard care in people with interstitial lung disease...
European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of...
Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)
This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the...
Comparison of PR Efficiency in Home-based With Hospital-based PR in Bronchiectasis
The investigators aimed to compare the home-based Pulmonary Rehabilitation with the hospital-based pulmonary rehabilitation in terms of pulmonary rehabilitation efficiency in...
Cough Capture as a Portal Into the Lung
The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing...
Explore Other Conditions
Frequently Asked Questions
There are currently 5 clinical trials for Lung Diseases, Interstitial, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Lung Diseases, Interstitial, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Lung Diseases, Interstitial, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.